Sanofi, Advent finalize negotiations for acquisition of Zentiva

This article was originally published here

Sanofi and Advent International have completed negotiations for the acquisition of Zentiva, Sanofi’s European generics business, by Advent and the companies have signed a Share Purchase Agreement worth €1.9bn (enterprise value).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply